Linaclotide in the management of gastrointestinal tract disorders

Brian E. Lacy, J. M. Levenick, M. D. Crowell

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Chronic constipation is a highly prevalent, heterogeneous disorder that significantly affects patients' lives. Nearly 15% of the U.S. population meets diagnostic criteria for chronic constipation (1). Chronic constipation reduces patients' quality of life and imposes a significant economic burden to the healthcare system (2, 3). A number of therapeutic options are currently available to treat symptoms of chronic constipation, although they are not universally successful (4, 5). Irritable bowel syndrome (IBS) is another common functional gastrointestinal disorder, with a prevalence rate estimated at up to 12% in the U.S. (6). Similar to chronic constipation, IBS imposes a significant impact on both the healthcare system and the individual patient (7-12). Currently, only one medication (lubiprostone) is approved by the U.S. Food and Drug Administration for the treatment of IBS with constipation (IBS-C), and is approved only for women (13). Although effective in many patients, it is not universally effective for the treatment of constipation symptoms in all patients with IBS-C. Other treatment options are therefore needed for those patients with chronic constipation and IBS-C who fail currently available therapies. This article will present information on the pharmacology and pharmacokinetics of linaclotide, a new agent designed to treat symptoms of both chronic constipation and IBS-C. Preclinical data, clinical studies and safety data will also be reviewed.

Original languageEnglish (US)
Pages (from-to)197-206
Number of pages10
JournalDrugs of Today
Volume48
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Constipation
Gastrointestinal Tract
Irritable Bowel Syndrome
Delivery of Health Care
Therapeutics
linaclotide
Gastrointestinal Diseases
United States Food and Drug Administration
Pharmacokinetics
Economics
Quality of Life
Pharmacology
Safety

Keywords

  • Abdominal pain
  • Constipation
  • Guanylate cyclase
  • Irritable bowel syndrome
  • Linaclotide

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Linaclotide in the management of gastrointestinal tract disorders. / Lacy, Brian E.; Levenick, J. M.; Crowell, M. D.

In: Drugs of Today, Vol. 48, No. 3, 03.2012, p. 197-206.

Research output: Contribution to journalArticle

Lacy, Brian E. ; Levenick, J. M. ; Crowell, M. D. / Linaclotide in the management of gastrointestinal tract disorders. In: Drugs of Today. 2012 ; Vol. 48, No. 3. pp. 197-206.
@article{ae846225716148a3a0b585e605bd2ef7,
title = "Linaclotide in the management of gastrointestinal tract disorders",
abstract = "Chronic constipation is a highly prevalent, heterogeneous disorder that significantly affects patients' lives. Nearly 15{\%} of the U.S. population meets diagnostic criteria for chronic constipation (1). Chronic constipation reduces patients' quality of life and imposes a significant economic burden to the healthcare system (2, 3). A number of therapeutic options are currently available to treat symptoms of chronic constipation, although they are not universally successful (4, 5). Irritable bowel syndrome (IBS) is another common functional gastrointestinal disorder, with a prevalence rate estimated at up to 12{\%} in the U.S. (6). Similar to chronic constipation, IBS imposes a significant impact on both the healthcare system and the individual patient (7-12). Currently, only one medication (lubiprostone) is approved by the U.S. Food and Drug Administration for the treatment of IBS with constipation (IBS-C), and is approved only for women (13). Although effective in many patients, it is not universally effective for the treatment of constipation symptoms in all patients with IBS-C. Other treatment options are therefore needed for those patients with chronic constipation and IBS-C who fail currently available therapies. This article will present information on the pharmacology and pharmacokinetics of linaclotide, a new agent designed to treat symptoms of both chronic constipation and IBS-C. Preclinical data, clinical studies and safety data will also be reviewed.",
keywords = "Abdominal pain, Constipation, Guanylate cyclase, Irritable bowel syndrome, Linaclotide",
author = "Lacy, {Brian E.} and Levenick, {J. M.} and Crowell, {M. D.}",
year = "2012",
month = "3",
doi = "10.1358/dot.2012.48.3.1745228",
language = "English (US)",
volume = "48",
pages = "197--206",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "3",

}

TY - JOUR

T1 - Linaclotide in the management of gastrointestinal tract disorders

AU - Lacy, Brian E.

AU - Levenick, J. M.

AU - Crowell, M. D.

PY - 2012/3

Y1 - 2012/3

N2 - Chronic constipation is a highly prevalent, heterogeneous disorder that significantly affects patients' lives. Nearly 15% of the U.S. population meets diagnostic criteria for chronic constipation (1). Chronic constipation reduces patients' quality of life and imposes a significant economic burden to the healthcare system (2, 3). A number of therapeutic options are currently available to treat symptoms of chronic constipation, although they are not universally successful (4, 5). Irritable bowel syndrome (IBS) is another common functional gastrointestinal disorder, with a prevalence rate estimated at up to 12% in the U.S. (6). Similar to chronic constipation, IBS imposes a significant impact on both the healthcare system and the individual patient (7-12). Currently, only one medication (lubiprostone) is approved by the U.S. Food and Drug Administration for the treatment of IBS with constipation (IBS-C), and is approved only for women (13). Although effective in many patients, it is not universally effective for the treatment of constipation symptoms in all patients with IBS-C. Other treatment options are therefore needed for those patients with chronic constipation and IBS-C who fail currently available therapies. This article will present information on the pharmacology and pharmacokinetics of linaclotide, a new agent designed to treat symptoms of both chronic constipation and IBS-C. Preclinical data, clinical studies and safety data will also be reviewed.

AB - Chronic constipation is a highly prevalent, heterogeneous disorder that significantly affects patients' lives. Nearly 15% of the U.S. population meets diagnostic criteria for chronic constipation (1). Chronic constipation reduces patients' quality of life and imposes a significant economic burden to the healthcare system (2, 3). A number of therapeutic options are currently available to treat symptoms of chronic constipation, although they are not universally successful (4, 5). Irritable bowel syndrome (IBS) is another common functional gastrointestinal disorder, with a prevalence rate estimated at up to 12% in the U.S. (6). Similar to chronic constipation, IBS imposes a significant impact on both the healthcare system and the individual patient (7-12). Currently, only one medication (lubiprostone) is approved by the U.S. Food and Drug Administration for the treatment of IBS with constipation (IBS-C), and is approved only for women (13). Although effective in many patients, it is not universally effective for the treatment of constipation symptoms in all patients with IBS-C. Other treatment options are therefore needed for those patients with chronic constipation and IBS-C who fail currently available therapies. This article will present information on the pharmacology and pharmacokinetics of linaclotide, a new agent designed to treat symptoms of both chronic constipation and IBS-C. Preclinical data, clinical studies and safety data will also be reviewed.

KW - Abdominal pain

KW - Constipation

KW - Guanylate cyclase

KW - Irritable bowel syndrome

KW - Linaclotide

UR - http://www.scopus.com/inward/record.url?scp=84859719909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859719909&partnerID=8YFLogxK

U2 - 10.1358/dot.2012.48.3.1745228

DO - 10.1358/dot.2012.48.3.1745228

M3 - Article

C2 - 22462039

AN - SCOPUS:84859719909

VL - 48

SP - 197

EP - 206

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 3

ER -